Executive Summary
Empasiprubart is a potent C2 complement sweeping antibody with sustained grip strength improvement in MMN Phase 2, heading into its first Phase 3 readout in a market expected to exceed $1B by 2030.
Empasiprubart
C2 · Antibody (C2 sweeping antibody)
Target: C2
Full NameComplement Component 2
PathwayComplement cascade (classical and lectin pathways)
Mechanism of Action[Corp '26 S20]
TypeC2 sweeping antibody
DescriptionPotent sweeping antibody that binds C2 and accelerates its clearance, inhibiting classical and lectin complement pathways
DifferentiationSweeping antibody technology; first targeted treatment being developed in MMN
Indications: MMN (Multifocal Motor Neuropathy)CIDPAMRSclerodermaAIEDGFALSSMA
Target Biology[Corp '26 S19]
C2 is a key component of the complement system, part of the immune system's attack machinery. By sweeping C2 from the blood, empasiprubart blocks the complement cascade that damages nerves and tissues in autoimmune diseases.
Clinical Data
ARDA Phase 2[Corp '26 S19]
Phase 2 Completed n=Cohort 1: EMP N=18, PBO N=9; Cohort 2: EMP N=18, PBO N=9 (at baseline)Endpoints
| Endpoint | Result | ||
|---|---|---|---|
Primary: Grip strength change from baseline (kPA)[Corp '26 S19] Change from baseline in grip strength measured in kiloPascals |
Grip strength curves shown (slide 19): EMP-EMP Cohort 2 ~20-25 kPA improvement at week 16; EMP-EMP Cohort 1 ~15 kPA at week 16; PBO-EMP Cohort 1 ~2-5 kPA; PBO-EMP Cohort 2 ~0 kPA. Numeric values estimated from graph. No p-values provided. | ||
ARDA+ Open Label Extension[Corp '26 S19]
Phase 2 OLE Ongoing n=EMP-EMP Cohort 1: 15 at wk64; Cohort 2: 12 at wk64; PBO-EMP Cohort 1: 5; Cohort 2: 6Endpoints
| Endpoint | Result | ||
|---|---|---|---|
Primary: Grip strength change from baseline (kPA) — sustained[Corp '26 S19] |
Sustained improvement through 64 weeks: EMP-EMP Cohort 2 reached ~35-40 kPA; Cohort 1 ~20 kPA at week 64. PBO-EMP cohorts showed lower improvements after crossover (~15 kPA Cohort 1, ~5 kPA Cohort 2). Numeric values estimated from graph. | ||
EMPASSION[Corp '26 S26]
Phase 3 Readout expected 4Q 2026CIDP Phase 3[Corp '26 S24]
Phase 3 Readout expected 2H 2027ADAPT Forward (combination: efgartigimod + empasiprubart)[Corp '26 S16]
Combination study ExploringCompetitive Landscape
Competitors
| Drug | Company | Limitation |
|---|---|---|
| IVIg | Multiple (PPTA, Takeda, CSL) | 60% progression despite treatment; not targeted |
Investment Analysis
Satya Bio Analysis — estimates based on public data and analyst judgment, not sourced from company materials
Bull Case
| Thesis Point | Supporting Evidence | Confidence |
|---|---|---|
| First targeted treatment in MMN with >$1B market opportunity | Slide 18 market data | Medium |
| Sustained 64-week grip strength improvement in OLE | ARDA+ data (slide 19) | Medium |
Bear Case
| Risk | Evidence | Mitigating Factors |
|---|---|---|
| Phase 3 head-to-head vs IVIg is challenging design | Slide 26 trial description | — |
| Phase 2 N=9-18 per arm; clinical significance of grip strength improvement uncertain | Slide 19 sample sizes | — |
Key Debates
| Question | Bull View | Bear View | Resolution Catalyst |
|---|---|---|---|
| Can empasiprubart beat IVIg head-to-head in MMN? | IVIg only manages disease; 60% still progress; empasiprubart targets root cause | IVIg is a proven therapy; head-to-head superiority is a high bar | EMPASSION Phase 3 readout 4Q 2026 |
Market Opportunity[JPM '26 S18]✓
Catalysts & Upcoming Events
| Event | Timing | Importance | Key Metrics to Watch | Consensus |
|---|---|---|---|---|
| EMPASSION Phase 3 MMN readout | 4Q 2026 | critical | Head-to-head vs IVIg. First targeted treatment in MMN. Supported by ARDA Phase 2 showing sustained grip strength improvement. | — |
| EMVIGORATE + EMNERGIZE Phase 3 CIDP readout | 2H 2027 | high | Co-positioning with VYVGART in CIDP. Expanding addressable market. | — |
| VARVARA Phase 2 DGF decision | Mid-2026 | medium | 52-week efficacy analysis to inform development decision in delayed graft function. | — |
| ADAPT-Forward combination with efgartigimod in AChR+ gMG | Ongoing | medium | Exploring empasiprubart as add-on therapy to efgartigimod for deeper efficacy. | — |
| MMN Phase 3 data readout (EMPASSION) | 4Q 2026 | critical | Head-to-head trial vs IVIg; first targeted treatment in MMN where 60% of patients progress despite current treatment | — |
| CIDP Phase 3 data readout | 2H 2027 | high | Co-positioning with VYVGART in CIDP; expanding beyond current 12K addressable market toward 42K total diagnosed patients | — |
| EMVIGORATE + EMNERGIZE Phase 3 data (CIDP) | 2H 2027 | high | Two CIDP studies. Co-positioning with VYVGART to expand beyond 12K current addressable to 42K total diagnosed. | — |
| VARVARA Phase 2 DGF decision (52-week efficacy analysis) | Mid-2026 | medium | Delayed graft function in kidney transplant. Decision on further development after full efficacy analysis. | — |